Core Insights - Septerna, Inc. is set to present data from its Phase 1 clinical trial of SEP-631 at the 2026 AAAAI Annual Meeting, highlighting its focus on G protein-coupled receptor drug discovery [1] - SEP-631 is a selective oral small molecule negative allosteric modulator targeting MRGPRX2, aimed at treating chronic spontaneous urticaria and other mast cell-driven diseases [2][3] Group 1: Clinical Trial and Presentation - The Phase 1 clinical trial data for SEP-631 will be presented during the Late Breaking Poster Session II on March 1, 2026, at the Pennsylvania Convention Center [2] - The study utilizes short wave infrared imaging to assess responses to an Icatibant skin challenge, indicating innovative methodologies in clinical research [2] Group 2: Drug Mechanism and Development - SEP-631 targets MRGPRX2, which is crucial for mast cell activation and degranulation, contributing to symptoms in various diseases including asthma and atopic dermatitis [2] - Preclinical studies have shown that SEP-631 effectively inhibits MRGPRX2 and prevents mediator-induced skin extravasation in mice, demonstrating its potential efficacy [2] Group 3: Company Overview - Septerna, Inc. is a clinical-stage biotechnology company with expertise in GPCR therapies, aiming to address significant unmet medical needs through its proprietary Native Complex Platform™ [3] - The company is advancing a diverse pipeline of novel oral small molecule drug candidates across multiple therapeutic areas, including endocrinology and immunology [3]
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting